Clinical efficacy and safety of basal insulin analogue glargine in patients with type 2 diabetes mellitus
Abstract
Basal insulin has a clearly defined position in the recommendations for the treatment of patients with type 2 diabetes mellitus. General most common indication for administration is the addition in situation of the failure of noninsulin antidiabetic therapy or early insulin treatment of diabetes, as one of the second choice after metformin.
In the recent years there is significant expansion of the range of antidiabetic drugs, including basal insulin analogues. In connection with the introduction of concentrated long-acting basal insulin analogues into the clinical practice many questions regarding clinical efficacy and safety raises especially comparing with the "classical" basal insulin analogues.
Although it is very likely that in the current clinical practice these differences in a number of indications are of minimal impact, it is possible that in some situations clinically relevant differences can be found among the basal insulin analogues.